Etabx

Etabx is a preclinical-stage biotechnology company focused on developing next-generation exosome-based therapeutics. The company leverages its proprietary Engineered Targeted Bionic Exosomes (ETABX) platform to overcome the delivery challenges associated with modern medicine, such as poor tissue specificity and immunogenicity. By engineering exosomes to carry diverse payloads including mRNA, siRNA, and proteins, Etabx aims to provide a safer and more effective alternative to lipid nanoparticles and viral vectors. Their research programs primarily target oncology, inflammatory diseases, and rare genetic disorders. Headquartered in Philadelphia, Etabx is positioned at the forefront of the rapidly evolving field of extracellular vesicle-mediated drug delivery.